# Xenon Pharmaceuticals (XENE) — Earnings

XENE · NASDAQ · Stock

Canonical page: https://www.lighthorse.io/tickers/xene/earnings

## Most recent quarter

| Metric | Value |
| --- | --- |
| Fiscal period | Q2 2026 |
| Period end | Jun 30, 2026 |
| EPS actual | −$1.11 |
| EPS estimate | −$1.14 |
| EPS surprise | +2.76% |
| Revenue surprise | −100.00% |
| Revenue | $0.00 |
| Revenue estimate | $1.7M |
| Reported | Aug 6, 2026 |
| SEC filing | [View filing](https://www.sec.gov:443/Archives/edgar/data/1582313/000119312526338244/xene-20260630.htm) |
| Earnings call | [Transcript](http://o.thsi.cn/dc-d-stock-america.teleconference/2b7456a8-140f-4440-166a-3d98490516dd.html) |

Xenon Pharmaceuticals reported Q2 2026 results on August 6, 2026. It posted a loss of $1.11 per share, slightly narrower than the $1.14 loss analysts expected, a beat of 2.76%. No revenue was reported for the quarter, against a $1.7 million estimate. In Q2 2025, the loss was $1.07 per share, so the loss widened by about 3.7%.

Every quarter in the table is a loss, and losses have grown over time. Annual losses were $2.04 per share in 2022, $2.72 in 2023 and $3.02 in 2024. The table has no Q4 2025 row, so 2025 has no full-year total here. The widest quarterly loss in the table was $1.17 in Q1 2026. Revenue appears only in some quarters and is blank in most recent ones. The latest figure shown is $7.5 million in Q1 2025. Over the 20 quarters in the table, Xenon beat the EPS estimate 12 times and missed it eight times.

Xenon reported Q3 results between November 3 and November 12 in each of the past five years. That points to early or mid-November 2026 for the next report, which will show where the loss per share lands against recent quarters.

## Earnings history

| Fiscal period | Report date | EPS estimate | EPS actual | Surprise | Revenue estimate | Revenue actual |
| --- | --- | --- | --- | --- | --- | --- |
| Q2 2026 | Aug 6, 2026 | −$1.14 | −$1.11 | 2.76% | $1.7M | — |
| Q1 2026 | May 7, 2026 | −$1.18 | −$1.17 | 0.81% | $1.4M | — |
| Q3 2025 | Nov 3, 2025 | −$1.15 | −$1.15 | 0.21% | — | — |
| Q2 2025 | Aug 11, 2025 | −$0.99 | −$1.07 | -8.37% | — | — |
| Q1 2025 | May 12, 2025 | −$0.90 | −$0.83 | 7.39% | $2.7M | $7.5M |
| Q4 2024 | Feb 27, 2025 | −$0.86 | −$0.84 | 2.38% | $357,143.00 | — |
| Q3 2024 | Nov 12, 2024 | −$0.82 | −$0.81 | 0.69% | — | — |
| Q2 2024 | Aug 8, 2024 | −$0.70 | −$0.75 | -7.11% | — | — |
| Q1 2024 | May 9, 2024 | −$0.66 | −$0.62 | 6.65% | — | — |
| Q4 2023 | Feb 29, 2024 | −$0.76 | −$0.64 | 15.70% | $2.3M | — |
| Q3 2023 | Nov 8, 2023 | −$0.77 | −$0.73 | 5.68% | $1.6M | — |
| Q2 2023 | Aug 9, 2023 | −$0.70 | −$0.72 | -3.36% | $461,538.00 | — |
| Q1 2023 | May 9, 2023 | −$0.62 | −$0.63 | -1.45% | $615,385.00 | — |
| Q4 2022 | Mar 1, 2023 | −$0.58 | −$0.57 | 2.55% | $2.9M | — |
| Q3 2022 | Nov 8, 2022 | −$0.52 | −$0.57 | -9.62% | $4.2M | $132,000.00 |
| Q2 2022 | Aug 9, 2022 | −$0.48 | −$0.55 | -13.87% | $4.2M | $536,000.00 |
| Q1 2022 | May 10, 2022 | −$0.41 | −$0.35 | 13.71% | $7.7M | $8.8M |
| Q4 2021 | Mar 1, 2022 | −$0.37 | −$0.48 | -29.35% | $5.7M | $3.7M |
| Q3 2021 | Nov 10, 2021 | −$0.38 | −$0.36 | 6.08% | $10.2M | $8.1M |
| Q2 2021 | Aug 11, 2021 | −$0.48 | −$0.51 | -6.52% | $2.7M | $2.2M |

## Frequently Asked Questions

### When did Xenon Pharmaceuticals (XENE) last report earnings?

Xenon Pharmaceuticals last reported on Aug 6, 2026, covering fiscal Q2 2026.

### Did XENE beat earnings estimates?

Yes. Xenon Pharmaceuticals reported EPS of −$1.11 for Q2 2026 against a −$1.14 estimate — a 2.76% beat.

---

Earnings figures may be restated, revised or corrected by the issuer. Past results do not indicate future performance.

This page is for informational purposes only. Nothing on it is a recommendation, solicitation or offer to buy or sell any security, nor investment, legal or tax advice. Light Horse Securities Inc does not verify third-party data and is not responsible for its accuracy, completeness or timeliness.

Data provided by [AInvest](https://www.ainvest.com).